Journal ArticleDOI
Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy.
Reads0
Chats0
TLDR
A review of GSH depletion-based cancer therapies can be found in this article, where the authors present some current challenges and future perspectives for GSH-depleting nanomedicine based cancer therapies.Abstract:
Cancer cells frequently exhibit resistance to various molecular and nanoscale drugs, which inevitably affects the drugs' therapeutic outcomes. Overexpression of glutathione (GSH) has been observed in many cancer cells, and solid evidence has corroborated the resulting tumor resistance to a variety of anticancer therapies, suggesting that this biochemical characteristic of cancer cells can be developed as a potential target for cancer treatments. The single treatment of GSH-depleting agents can potentiate the responses of the cancer cells to different cell death stimuli; therefore, as an adjunctive strategy, GSH depletion is usually combined with mainstream cancer therapies for enhancing the therapeutic outcomes. Propelled by the rapid development of nanotechnology, GSH-depleting agents can be readily constructed into anticancer nanomedicines, which have shown a steep rise over the past decade. Here, we review the common GSH-depleting nanomedicines which have been widely applied in synergistic cancer treatments in recent years. Some current challenges and future perspectives for GSH depletion-based cancer therapies are also presented. With the understanding of the structure-property relationship and action mechanisms of these biomaterials, we hope that the GSH-depleting nanotechnology will be further developed to realize more effective disease treatments and even achieve successful clinical translations.read more
Citations
More filters
Journal ArticleDOI
Chemodynamic Therapy via Fenton and Fenton-Like Nanomaterials: Strategies and Recent Advances.
Chenyang Jia,Yuxin Guo,Fu-Gen Wu +2 more
TL;DR: In this article, the latest advancements in the nanomaterials-involved CDT from 2018 to the present and proposes the current limitations as well as future research directions in the related field.
Journal ArticleDOI
Strategies for enhancing cancer chemodynamic therapy performance
TL;DR: In this article , the fundamental understanding of Fenton and Fenton-like reactions and their relationship with CDT is highlighted in a general manner, and recent advancement of the strategies to augment Fenton reactions in tumor microenvironment (TME) for enhanced CDT are discussed in detail.
Journal ArticleDOI
A Metabolic Multistage Glutathione Depletion Used for Tumor-Specific Chemodynamic Therapy.
TL;DR: A multistage GSH-consuming and tumor-specific CDT that fabricates nanomedicine with GSH exhausted function for highly potent CDT but also uses metabolic differences to achieve tumor- specific therapy.
Journal ArticleDOI
Coordinating the Mechanisms of Action of Ferroptosis and the Photothermal Effect for Cancer Theranostics
TL;DR: In this paper , a cancer theranostic nanomedicine formula was developed by considering the mechanisms of action of ferroptosis and the photothermal effect in combination therapy, where the croconaine molecule was encapsulated as both a photothermal converter and an iron-chelating agent with BSA, thus leading to biocompatible and stable Cro-Fe@BSA nanoparticles.
Journal ArticleDOI
Copper-Based Metal-Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis.
Jian Liu,Ye Yuan,Yan-Ming Cheng,Daan Fu,Zhongyin Chen,Yan Wang,Lifa Zhang,Chundong Yao,Lin Shi,Mingyi Li,Cheng-peng Zhou,Meizhen Zou,Guobin Wang,Lin Wang,Zheng Wang +14 more
TL;DR: Along with CuHPT's good biocompatibility, biochemical, cell biological, preclinical animal model data provide compelling evidence supporting the notion that this copper-based MOF is a predesigned smart therapeutic against drug-resistant cancers through precisely deconstructing their redox homeostasis.
References
More filters
Journal ArticleDOI
Photodynamic therapy for cancer
TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
Journal ArticleDOI
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
TL;DR: It is argued that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Journal ArticleDOI
Signal transduction by the JNK group of MAP kinases.
TL;DR: This review will focus on the JNK group of MAP kinases, which are characterized by the sequence TEY and the two stress-activatedMAP kinases: p38 with the sequence TGY, and the c-Jun NH2-terminal kinases (JNK) with the sequences TPY.
Journal ArticleDOI
Glutathione Metabolism and Its Implications for Health
TL;DR: Animal and human studies demonstrate that adequate protein nutrition is crucial for the maintenance of GSH homeostasis, and compelling evidence shows that GSH synthesis is regulated primarily by gamma-glutamylcysteine synthetase activity, cysteine availability, and GSH feedback inhibition.
Journal ArticleDOI
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
Susan P.C. Cole,Gabu Bhardwaj,James H. Gerlach,J. E. Mackie,Caroline E. Grant,Kurt C. Almquist,Alistair J. Stewart,Ebba U. Kurz,A. M. V. Duncan,Roger G. Deeley +9 more
TL;DR: Reversion to drug sensitivity was associated with loss of gene amplification and a marked decrease in mRNA expression, and the mRNA encodes a member of the ATP-binding cassette transmembrane transporter superfamily.